Bifidumbacterin, and topical application 5 doses 10 pcs

Pharmacotherapeutic group

Medical immunobiological drug – probiotic. ATX code: A07FA.

BIOLOGICAL PROPERTIES

Therapeutic properties of the drug are determined by live lyophilized bifidobacteria (Bifidobacterium bifidum) inherent in humans since birth with antagonistic activity against a wide range of pathogenic and conditionally pathogenic microorganisms. The high quantitative level of bifidobacteria in the preparation helps to normalize the intestinal microflora and thus improve the activity of the gastrointestinal tract, metabolic processes, and intestinal digestion, and increase nonspecific resistance of the organism.

Indications

Dysbacteriosis of the intestines of various etiologies.

In the complex therapy: intestinal dysfunctions of unspecified etiology; acute intestinal infections (dysentery, salmonellosis, escherichiosis, yersiniosis, rotavirus infection of unspecified etiology); patients with relapses after acute intestinal infections;

Chronic diseases of the digestive system with abnormal intestinal microflora;

Chronic diseases of the digestive system with abnormal intestinal microflora Children (including newborns and prematurely born) with pneumonia, sepsis and other purulent-infectious diseases; as well as those with anemia, hypotrophy, rickets to reduce complications and increase the effectiveness of the main treatment; Allergic diseases;

dysbiosis and inflammatory processes of the female genitalia (bacterial vaginosis, including in pregnant women, bacterial colpitis, and senile colpitis of hormonal nature).

To prevent dysbacteriosis when taking antibacterial drugs (including antibiotics), glucocorticosteroids, drugs that have a ulcerogenic effect on the gastrointestinal tract (including. NSAIDs);

In radiation and chemotherapy;

Stress and extremes; children of all ages with frequent illnesses;

Children with a history of pre-morbid conditions, those born prematurely or with signs of prematurity and those who received antibiotics in the early neonatal period. Children whose mothers have had severe toxemia, extragenital diseases, prolonged waterless period, lactastasis, cracked nipples and resumed breastfeeding after recovery from mastitis;

In infants when they are switched to artificial feeding and donor milk feeding at an early age.

In order to prevent mastitis for local mammary gland treatment in breastfeeding mothers of the “risk” group (in women with inverted flat nipple, decreased nipple erection, the presence of cracks).

Active ingredient

Composition

the active substance – bifidobacteria – at least 500 million (5×108 CFU)

excipient – lactose monohydrate – up to 0.85 g

How to take, the dosage

The number of times the drug can be increased up to 6 times a day, if necessary.

The course of treatment 3-4 weeks. If necessary, the course of treatment can be repeated 2-3 times, each time in a month.

In acute cases of severe disease with severe dysbacteriosis the daily dose of the drug may be increased only by the doctor’s prescription. When using the drug in the complex treatment of acute intestinal infections the course of treatment is 7-10 days. For preventive purposes:

Interaction

Special Instructions

Synopsis

Contraindications

Side effects

Overdose

Pregnancy use

Similarities